Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

2.

Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.

Kleinschmidt EG, Miller NLG, Ozmadenci D, Tancioni I, Osterman CD, Barrie AM, Taylor KN, Ye A, Jiang S, Connolly DC, Stupack DG, Schlaepfer DD.

Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.

PMID:
31308489
3.

CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.

Gao R, Li D, Xun J, Zhou W, Li J, Wang J, Liu C, Li X, Shen W, Qiao H, Stupack DG, Luo N.

Theranostics. 2018 Nov 29;8(22):6248-6262. doi: 10.7150/thno.28721. eCollection 2018.

4.

PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.

Gao R, Liu Y, Li D, Xun J, Zhou W, Wang P, Liu C, Li X, Shen W, Su W, Qiao H, Stupack DG, Luo N.

Cell Physiol Biochem. 2018;50(6):2108-2123. doi: 10.1159/000495055. Epub 2018 Nov 9.

5.

FOXL2C134W-Induced CYP19 Expression via Cooperation With SMAD3 in HGrC1 Cells.

Belli M, Iwata N, Nakamura T, Iwase A, Stupack D, Shimasaki S.

Endocrinology. 2018 Apr 1;159(4):1690-1703. doi: 10.1210/en.2017-03207.

6.

Caspase-8 function, and phosphorylation, in cell migration.

Keller N, Ozmadenci D, Ichim G, Stupack D.

Semin Cell Dev Biol. 2018 Oct;82:105-117. doi: 10.1016/j.semcdb.2018.01.009. Epub 2018 Feb 17. Review.

PMID:
29410361
7.

Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation.

Hu S, Dong X, Gao W, Stupack D, Liu Y, Xiang R, Li N.

Oncotarget. 2017 Apr 28;8(34):56569-56581. doi: 10.18632/oncotarget.17507. eCollection 2017 Aug 22.

8.

Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.

Delaney JR, Patel CB, Willis KM, Haghighiabyaneh M, Axelrod J, Tancioni I, Lu D, Bapat J, Young S, Cadassou O, Bartakova A, Sheth P, Haft C, Hui S, Saenz C, Schlaepfer DD, Harismendy O, Stupack DG.

Nat Commun. 2017 Feb 15;8:14423. doi: 10.1038/ncomms14423.

9.

Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00014. Epub 2017 Aug 15.

10.
11.

Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings.

Davis MA, Delaney JR, Patel CB, Storgard R, Stupack DG.

Drug Des Devel Ther. 2016 Jun 2;10:1837-46. doi: 10.2147/DDDT.S102241. eCollection 2016.

12.

JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms.

Zhang Y, Shen L, Stupack DG, Bai N, Xun J, Ren G, Han J, Li L, Luo Y, Xiang R, Tan X.

Oncotarget. 2016 May 17;7(20):29387-99. doi: 10.18632/oncotarget.8836.

13.

TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer.

Shen W, Chang A, Wang J, Zhou W, Gao R, Li J, Xu Y, Luo X, Xiang R, Luo N, Stupack DG.

Oncogenesis. 2015 Oct 26;4:e173. doi: 10.1038/oncsis.2015.30.

14.

A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.

Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG.

Oncotarget. 2015 Oct 13;6(31):31104-18. doi: 10.18632/oncotarget.5093.

15.

Role of Hyaluronan and Glucose on 4-Methylumbelliferone-inhibited Cell Proliferation in Breast Carcinoma Cells.

Wang R, Zhou W, Wang J, Liu Y, Chen Y, Jiang S, Luo X, Stupack DG, Luo N.

Anticancer Res. 2015 Sep;35(9):4799-805.

PMID:
26254370
16.

Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.

Young SA, McCabe KE, Bartakova A, Delaney J, Pizzo DP, Newbury RO, Varner JA, Schlaepfer DD, Stupack DG.

PLoS One. 2015 May 14;10(5):e0120815. doi: 10.1371/journal.pone.0120815. eCollection 2015.

17.

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.

McCabe KE, Bacos K, Lu D, Delaney JR, Axelrod J, Potter MD, Vamos M, Wong V, Cosford ND, Xiang R, Stupack DG.

Cell Death Dis. 2014 Oct 30;5:e1496. doi: 10.1038/cddis.2014.448.

18.

The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth.

Sayyah J, Bartakova A, Nogal N, Quilliam LA, Stupack DG, Brown JH.

J Biol Chem. 2014 Jun 20;289(25):17689-98. doi: 10.1074/jbc.M113.536227. Epub 2014 May 1.

19.

Rab5 is required in metastatic cancer cells for Caveolin-1-enhanced Rac1 activation, migration and invasion.

Díaz J, Mendoza P, Ortiz R, Díaz N, Leyton L, Stupack D, Quest AF, Torres VA.

J Cell Sci. 2014 Jun 1;127(Pt 11):2401-6. doi: 10.1242/jcs.141689. Epub 2014 Mar 21.

20.

Caspase-8 as a regulator of tumor cell motility.

Graf RP, Keller N, Barbero S, Stupack D.

Curr Mol Med. 2014 Feb;14(2):246-54. Review.

21.

Tumor angiogenesis: putting a value on plastic GEMMs.

Cheresh DA, Stupack DG.

Circ Res. 2014 Jan 3;114(1):9-11. doi: 10.1161/CIRCRESAHA.113.302812. No abstract available.

22.

SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells.

Chen S, Li X, Lu D, Xu Y, Mou W, Wang L, Chen Y, Liu Y, Li X, Li LY, Liu L, Stupack D, Reisfeld RA, Xiang R, Li N.

Carcinogenesis. 2014 Mar;35(3):613-23. doi: 10.1093/carcin/bgt371. Epub 2013 Nov 14.

PMID:
24233838
23.

Rab5 activation promotes focal adhesion disassembly, migration and invasiveness in tumor cells.

Mendoza P, Ortiz R, Díaz J, Quest AF, Leyton L, Stupack D, Torres VA.

J Cell Sci. 2013 Sep 1;126(Pt 17):3835-47. doi: 10.1242/jcs.119727. Epub 2013 Jun 26.

24.

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.

Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, Li Z, Luo N, Tan X, Luo N, Luo Y, Xiang R, Li X, Reisfeld RA, Stupack D, Lv D, Liu C.

Cancer Biol Ther. 2013 Jun;14(6):511-20. doi: 10.4161/cbt.24345.

25.

Src-inducible association of CrkL with procaspase-8 promotes cell migration.

Graf R, Barbero S, Keller N, Chen L, Uryu S, Schlaepfer D, Stupack D.

Cell Adh Migr. 2013 Jul-Aug;7(4):362-9. doi: 10.4161/cam.25284. Epub 2013 Jun 10.

26.

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD.

Clin Exp Metastasis. 2013 Jun;30(5):579-94. doi: 10.1007/s10585-012-9562-5. Epub 2012 Dec 30.

27.

EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.

Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA.

PLoS One. 2012;7(5):e36753. doi: 10.1371/journal.pone.0036753. Epub 2012 May 7.

28.

Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy.

Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA, Xiang R.

Cancer Res. 2012 Jul 15;72(14):3451-6. doi: 10.1158/0008-5472.CAN-11-2536. Epub 2012 May 14.

29.

Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer.

Wang L, Chen S, Zhang M, Li N, Chen Y, Su W, Liu Y, Lu D, Li S, Yang Y, Li Z, Stupack D, Qu P, Hu H, Xiang R.

J Cell Biochem. 2012 Aug;113(8):2679-86. doi: 10.1002/jcb.24143.

PMID:
22441772
30.

Caspase-8 isoform 6 promotes death effector filament formation independent of microtubules.

Yuan RT, Young S, Liang J, Schmid MC, Mielgo A, Stupack DG.

Apoptosis. 2012 Mar;17(3):229-35. doi: 10.1007/s10495-011-0677-y.

PMID:
22160860
31.

X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles.

Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi NC, Ruoslahti E, Stupack D, Sailor MJ.

Angew Chem Int Ed Engl. 2011 Dec 16;50(51):12308-11. doi: 10.1002/anie.201104507. Epub 2011 Oct 26. No abstract available.

32.

EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.

Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA.

Oncogene. 2012 May 31;31(22):2783-93. doi: 10.1038/onc.2011.450. Epub 2011 Oct 3.

33.

Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts.

DE Wever O, Sobczak-Thépot J, Vercoutter-Edouart AS, Michalski JC, Ouelaa-Benslama R, Stupack DG, Bracke M, Wang JYJ, Gespach C, Emami S.

Int J Oncol. 2011 Aug;39(2):393-400. doi: 10.3892/ijo.2011.1034. Epub 2011 May 9.

34.

Applications of a new In vivo tumor spheroid based shell-less chorioallantoic membrane 3-D model in bioengineering research.

De Magalhães N, Liaw LH, Berns M, Cristini V, Chen Z, Stupack D, Lowengrub J.

J Biomed Sci Eng. 2010 Jan 1;3(1):20-26.

35.

Rab5 in the regulation of cell motility and invasion.

Torres VA, Stupack DG.

Curr Protein Pept Sci. 2011 Feb;12(1):43-51. Review.

PMID:
21190523
36.

Caspase-8 as a therapeutic target in cancer.

Stupack DG.

Cancer Lett. 2013 May 28;332(2):133-40. doi: 10.1016/j.canlet.2010.07.022. Epub 2010 Sep 3. Review.

37.

Selection in spatial stochastic models of cancer: migration as a key modulator of fitness.

Thalhauser CJ, Lowengrub JS, Stupack D, Komarova NL.

Biol Direct. 2010 Apr 20;5:21. doi: 10.1186/1745-6150-5-21.

38.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):778-90.

39.

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):764-77.

40.

The death effector domains of caspase-8 induce terminal differentiation.

Mielgo A, Torres VA, Schmid MC, Graf R, Zeitlin SG, Lee P, Shields DJ, Barbero S, Jamora C, Stupack DG.

PLoS One. 2009 Nov 18;4(11):e7879. doi: 10.1371/journal.pone.0007879.

41.

Rab5 mediates caspase-8-promoted cell motility and metastasis.

Torres VA, Mielgo A, Barbero S, Hsiao R, Wilkins JA, Stupack DG.

Mol Biol Cell. 2010 Jan 15;21(2):369-76. doi: 10.1091/mbc.E09-09-0769. Epub 2009 Nov 18.

42.

Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules.

Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG.

Oncogene. 2009 Oct 8;28(40):3551-62. doi: 10.1038/onc.2009.210. Epub 2009 Aug 10.

43.

Agonizing integrin antagonists?

Weis SM, Stupack DG, Cheresh DA.

Cancer Cell. 2009 May 5;15(5):359-61. doi: 10.1016/j.ccr.2009.04.005.

44.

Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis.

Barbero S, Mielgo A, Torres V, Teitz T, Shields DJ, Mikolon D, Bogyo M, Barilà D, Lahti JM, Schlaepfer D, Stupack DG.

Cancer Res. 2009 May 1;69(9):3755-63. doi: 10.1158/0008-5472.CAN-08-3937. Epub 2009 Apr 21.

45.

Netrin-1 acts as a survival factor for aggressive neuroblastoma.

Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, Stupack D, Nakagawara A, Rousseau R, Combaret V, Puisieux A, Valteau-Couanet D, Bénard J, Bernet A, Mehlen P.

J Exp Med. 2009 Apr 13;206(4):833-47. doi: 10.1084/jem.20082299. Epub 2009 Apr 6.

46.

Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling.

Huang X, Wu D, Jin H, Stupack D, Wang JY.

J Cell Biol. 2008 Nov 17;183(4):711-23. doi: 10.1083/jcb.200801192. Epub 2008 Nov 10.

47.

Caspase 8 promotes peripheral localization and activation of Rab5.

Torres VA, Mielgo A, Barilà D, Anderson DH, Stupack D.

J Biol Chem. 2008 Dec 26;283(52):36280-9. doi: 10.1074/jbc.M805878200. Epub 2008 Oct 29.

48.

Regulation of angiogenesis: apoptotic cues from the ECM.

Cheresh DA, Stupack DG.

Oncogene. 2008 Oct 20;27(48):6285-98. doi: 10.1038/onc.2008.304. Review.

PMID:
18931694
49.

G protein-coupled receptors go extracellular: RhoA integrates the integrins.

Walsh CT, Stupack D, Brown JH.

Mol Interv. 2008 Aug;8(4):165-73. doi: 10.1124/mi.8.4.8. Review.

50.

Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61.

Walsh CT, Radeff-Huang J, Matteo R, Hsiao A, Subramaniam S, Stupack D, Brown JH.

FASEB J. 2008 Nov;22(11):4011-21. doi: 10.1096/fj.08-113266. Epub 2008 Aug 7.

Supplemental Content

Loading ...
Support Center